Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells.

Lertsuwan K, Peters W, Johnson L, Lertsuwan J, Marwa I, Sikes RA.

Anticancer Res. 2017 Feb;37(2):529-537.

PMID:
28179298
2.

Identification of Fibulin-1 as a Human Bone Marrow Stromal (HS-5) Cell-Derived Factor That Induces Human Prostate Cancer Cell Death.

Lertsuwan K, Choe LH, Marwa IR, Lee K, Sikes RA.

Prostate. 2017 May;77(7):729-742. doi: 10.1002/pros.23303. Epub 2017 Feb 7.

PMID:
28168724
3.

Transforming growth factor-β signaling induced during prostate cancer cell death and neuroendocrine differentiation is mediated by bone marrow stromal cells.

Miles FL, Kurtoglu S, Ahmer C, Soori M, Favate JS, Sikes RA.

Prostate. 2015 Nov;75(15):1802-13. doi: 10.1002/pros.23060. Epub 2015 Aug 26.

PMID:
26392321
4.
5.

Identification of beta-2 as a key cell adhesion molecule in PCa cell neurotropic behavior: a novel ex vivo and biophysical approach.

Jansson KH, Castillo DG, Morris JW, Boggs ME, Czymmek KJ, Adams EL, Schramm LP, Sikes RA.

PLoS One. 2014 Jun 3;9(6):e98408. doi: 10.1371/journal.pone.0098408. eCollection 2014.

6.

Insidious changes in stromal matrix fuel cancer progression.

Miles FL, Sikes RA.

Mol Cancer Res. 2014 Mar;12(3):297-312. doi: 10.1158/1541-7786.MCR-13-0535. Epub 2014 Jan 22. Review.

7.

Combination of low dose of genistein and daidzein has synergistic preventive effects on isogenic human prostate cancer cells when compared with individual soy isoflavone.

Dong X, Xu W, Sikes RA, Wu C.

Food Chem. 2013 Dec 1;141(3):1923-33. doi: 10.1016/j.foodchem.2013.04.109. Epub 2013 May 9.

PMID:
23870911
8.

Apoptotic effects of cooked and in vitro digested soy on human prostate cancer cells.

Dong X, Xu W, Sikes RA, Wu C.

Food Chem. 2012 Dec 1;135(3):1643-52. doi: 10.1016/j.foodchem.2012.06.023. Epub 2012 Jun 26.

PMID:
22953905
9.

Differential effects of vitamin D treatment on inflammatory and non-inflammatory breast cancer cell lines.

Hillyer RL, Sirinvasin P, Joglekar M, Sikes RA, van Golen KL, Nohe A.

Clin Exp Metastasis. 2012 Dec;29(8):971-9. doi: 10.1007/s10585-012-9486-0. Epub 2012 May 20.

PMID:
22610818
10.

Increased TGF-β1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling.

Miles FL, Tung NS, Aguiar AA, Kurtoglu S, Sikes RA.

Prostate. 2012 Sep 1;72(12):1339-50. doi: 10.1002/pros.22482. Epub 2012 Jan 6.

PMID:
22228025
11.

Overexpression of the VSSC-associated CAM, β-2, enhances LNCaP cell metastasis associated behavior.

Jansson KH, Lynch JE, Lepori-Bui N, Czymmek KJ, Duncan RL, Sikes RA.

Prostate. 2012 Jul 1;72(10):1080-92. doi: 10.1002/pros.21512. Epub 2011 Nov 29.

PMID:
22127840
12.

Effect of moderate-to-severe chronic kidney disease on flow-mediated dilation and progenitor cells.

Kuczmarski JM, Darocki MD, DuPont JJ, Sikes RA, Cooper CR, Farquhar WB, Edwards DG.

Exp Biol Med (Maywood). 2011 Sep;236(9):1085-92. doi: 10.1258/ebm.2011.011008. Epub 2011 Jul 26.

PMID:
21791552
13.

Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.

Zhang C, Soori M, Miles FL, Sikes RA, Carson DD, Chung LW, Farach-Carson MC.

Prostate. 2011 Feb 1;71(2):157-67. doi: 10.1002/pros.21231.

14.

Osteoblasts can stimulate prostate cancer growth and transcriptionally down-regulate PSA expression in cell line models.

Li Y, Sikes RA, Malaeb BS, Yeung F, Law A, Graham SE, Pei M, Kao C, Nelson J, Koeneman KS, Chung LW.

Urol Oncol. 2011 Nov-Dec;29(6):802-8. doi: 10.1016/j.urolonc.2009.09.016. Epub 2010 May 6.

PMID:
20451417
15.

Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells.

Degraff DJ, Aguiar AA, Chen Q, Adams LK, Williams BJ, Sikes RA.

Am J Transl Res. 2010 Mar 6;2(2):200-8.

16.

Short-term intermittent PTH 1-34 administration enhances bone formation in SCID/Beige mice.

Sheehan S, Muthusamy A, Paul E, Sikes RA, Gomes RR Jr.

Endocr J. 2010;57(5):373-82. Epub 2010 Feb 6.

17.

The developmental expression profile of PAX2 in the murine prostate.

Chen Q, DeGraff DJ, Sikes RA.

Prostate. 2010 May 1;70(6):654-65. doi: 10.1002/pros.21099.

PMID:
20017165
18.
19.

Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells.

Thalmann GN, Rhee H, Sikes RA, Pathak S, Multani A, Zhau HE, Marshall FF, Chung LW.

Eur Urol. 2010 Jul;58(1):162-71. doi: 10.1016/j.eururo.2009.08.026. Epub 2009 Sep 4.

20.

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation.

Gomes RR Jr, Buttke P, Paul EM, Sikes RA.

Clin Exp Metastasis. 2009;26(7):641-51. doi: 10.1007/s10585-009-9263-x. Epub 2009 May 7.

PMID:
19421879
21.

Quantitative modeling and analysis of the transforming growth factor beta signaling pathway.

Chung SW, Miles FL, Sikes RA, Cooper CR, Farach-Carson MC, Ogunnaike BA.

Biophys J. 2009 Mar 4;96(5):1733-50. doi: 10.1016/j.bpj.2008.11.050.

22.

Conserved gene expression programs integrate mammalian prostate development and tumorigenesis.

Pritchard C, Mecham B, Dumpit R, Coleman I, Bhattacharjee M, Chen Q, Sikes RA, Nelson PS.

Cancer Res. 2009 Mar 1;69(5):1739-47. doi: 10.1158/0008-5472.CAN-07-6817. Epub 2009 Feb 17.

23.

Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha.

Cooper CR, Graves B, Pruitt F, Chaib H, Lynch JE, Cox AK, Sequeria L, van Golen KL, Evans A, Czymmek K, Bullard RS, Donald CD, Sol-Church K, Gendernalik JD, Weksler B, Farach-Carson MC, Macoska JA, Sikes RA, Pienta KJ.

J Cell Biochem. 2008 Aug 15;104(6):2298-309. doi: 10.1002/jcb.21785.

24.

Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model.

Degraff DJ, Malik M, Chen Q, Miyako K, Rejto L, Aguiar AA, Bancroft DR, Cohen P, Sikes RA.

J Cell Physiol. 2007 Oct;213(1):261-8.

PMID:
17492783
25.

Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells.

Deeble PD, Cox ME, Frierson HF Jr, Sikes RA, Palmer JB, Davidson RJ, Casarez EV, Amorino GP, Parsons SJ.

Cancer Res. 2007 Apr 15;67(8):3663-72.

26.

Voltage-sensitive ion channels and cancer.

Fiske JL, Fomin VP, Brown ML, Duncan RL, Sikes RA.

Cancer Metastasis Rev. 2006 Sep;25(3):493-500. Review.

PMID:
17111226
27.

Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.

Tate A, Isotani S, Bradley MJ, Sikes RA, Davis R, Chung LW, Edlund M.

BMC Cancer. 2006 Jul 25;6:197.

28.

Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.

Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA.

Cancer Lett. 2006 Dec 8;244(2):274-88. Epub 2006 Feb 23.

PMID:
16500022
29.

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.

Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME.

Cancer Res. 2004 Dec 1;64(23):8620-9.

30.

Thalidomide and analogues: current proposed mechanisms and therapeutic usage.

Brennen WN, Cooper CR, Capitosti S, Brown ML, Sikes RA.

Clin Prostate Cancer. 2004 Jun;3(1):54-61. Review.

PMID:
15279692
31.

Cellular interactions in the tropism of prostate cancer to bone.

Sikes RA, Nicholson BE, Koeneman KS, Edlund NM, Bissonette EA, Bradley MJ, Thalmann GN, Cecchini MG, Pienta KJ, Chung LW.

Int J Cancer. 2004 Jul 1;110(4):497-503.

32.

Cancer cells homing to bone: the significance of chemotaxis and cell adhesion.

Cooper CR, Sikes RA, Nicholson BE, Sun YX, Pienta KJ, Taichman RS.

Cancer Treat Res. 2004;118:291-309. Review. No abstract available.

PMID:
15043197
33.

Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers.

Sikes RA, Walls AM, Brennen WN, Anderson JD, Choudhury-Mukherjee I, Schenck HA, Brown ML.

Clin Prostate Cancer. 2003 Dec;2(3):181-7. Review.

PMID:
15040863
34.
35.

Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostate.

Abbott DE, Pritchard C, Clegg NJ, Ferguson C, Dumpit R, Sikes RA, Nelson PS.

Genome Biol. 2003;4(12):R79. Epub 2003 Nov 28.

36.

Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3.

Anderson JD, Hansen TP, Lenkowski PW, Walls AM, Choudhury IM, Schenck HA, Friehling M, Höll GM, Patel MK, Sikes RA, Brown ML.

Mol Cancer Ther. 2003 Nov;2(11):1149-54.

37.
38.
39.

The role of insulin-like growth factor-II in cancer growth and progression evidenced by the use of ribozymes and prostate cancer progression models.

Guo N, Ye JJ, Liang SJ, Mineo R, Li SL, Giannini S, Plymate SR, Sikes RA, Fujita-Yamaguchi Y.

Growth Horm IGF Res. 2003 Feb;13(1):44-53.

PMID:
12550081
40.
41.

Integrin expression and usage by prostate cancer cell lines on laminin substrata.

Edlund M, Miyamoto T, Sikes RA, Ogle R, Laurie GW, Farach-Carson MC, Otey CA, Zhau HE, Chung LW.

Cell Growth Differ. 2001 Feb;12(2):99-107.

42.

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW.

Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2).

PMID:
10881018
43.

Distribution of IGFBP-rP1 in normal human tissues.

Degeorges A, Wang F, Frierson HF Jr, Seth A, Sikes RA.

J Histochem Cytochem. 2000 Jun;48(6):747-54.

PMID:
10820148
44.

Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer.

Hyytinen ER, Frierson HF Jr, Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LW, Dong JT.

Prostate. 1999 Nov 1;41(3):190-5.

PMID:
10517877
45.

Osteopontin: possible role in prostate cancer progression.

Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW.

Clin Cancer Res. 1999 Aug;5(8):2271-7.

46.

Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1.

Degeorges A, Wang F, Frierson HF Jr, Seth A, Chung LW, Sikes RA.

Cancer Res. 1999 Jun 15;59(12):2787-90.

47.

Molecular determination of surgical margins using fossa biopsies at radical prostatectomy.

Theodorescu D, Frierson HF Jr, Sikes RA.

J Urol. 1999 May;161(5):1442-8.

PMID:
10210369
48.
49.

Supplemental Content

Loading ...
Support Center